Home › Asthma › NCT07166939
45th Multicenter Airway Research Collaboration
RecruitingPhase 4
A Phase 4, Multicenter, Cluster Randomized, Open-label, Intervention Versus Usual Care, Controlled Study on the Effect of Emergency Department Initiation of Airsupra on Asthma Outcomes
Who can join
Ages 18 to 54 · All sexes
Full eligibility criteria
INCLUSION CRITERIA: * acute asthma * age 18.0 to 54.9 years * English and/or Spanish speaking * decision by ED attending to discharge patient to home on short course of systemic corticosteroids * (intervention group only) Willingness to use Airsupra as their rescue inhaler for next 3 months * demonstration of acceptable MDI administration technique * provision of informed consent prior to any study-specific procedures EXCLUSION CRITERIA: * involvement in the planning and/or conduct of the study * previous enrolment in the present study * prior diagnosis of COPD, chronic bronchitis, or emphysema * use of systemic corticosteroids in the past 2 weeks * participation in another clinical study with an investigational product during the past 4 weeks or the 3 months after enrollment in the current study * concurrent pneumonia * clinically significant cardiovascular disease or clinically significant cancer * patients with known hypersensitivity to Airsupra, albuterol sulfate, budesonide, or any of the excipients of the product * (for women only, by self-report): * currently pregnant * currently breastfeeding, * (among sexually active women of child-bearing age only) not using adequate contraception over the last 3 months, or no plan to use adequate contraception over the next 3 months * lack of a working cell phone and working email address * expected lack of availability for text and/or telephone follow-up at approximately 3, 6, and 12 weeks after the ED visit * inability to provide an alternate contact with a working cell phone and working email address.
About the study
The study is a randomized controlled trial on the effect of emergency department initiation of Airsupra on acute asthma "recurrence" at 3 months and other related outcomes (acute asthma relapse, asthma control).
What is being tested
- Airsupra (drug)
Sponsor: Massachusetts General Hospital · Participants: 1,860 · Started: Nov 7, 2025
Contact the study team
- Carlos A Camargo, MD, DrPH · Phone: 617-726-5276
Official record on ClinicalTrials.gov — NCT07166939
Locations in the U.S.
| Ohio | MetroHealth, Cleveland |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.